Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Pressure-Enabled Drug Delivery Device Compared to Standard Microcatheter for Radiotracer Delivery for Mapping Liver Cancer or Liver Metastases

Trial Status: active

This clinical trial compares a pressure-enabled drug delivery (PEDD) device to standard microcatheter for radiotracer delivery for mapping liver cancer or cancer that has spread to the liver (liver metastases) before radioembolization. Radioembolization refers to the delivery of radioactivity directly to the tumor through the artery that provides the blood supply to the tumor. The radioactivity is delivered in the form of tiny radioactive beads, known as microspheres, through a catheter that is positioned in the artery supplying the tumor. The radioactive microspheres stay in the arteries of the tumor and deliver a high dose of radiation to kill the tumor. Before a radioembolization procedure, another procedure called "mapping" is performed to look at the anatomy of tumors and their arteries in order to determine the right dose of radioactivity. Mapping is also used to plan where the radioactivity will be put to best protect the healthy tissue around the tumor and healthy organs. The purpose of the study is to determine if the type of catheter used in the mapping procedure improves the delivery of radioactivity to the tumor, which may lead to improved tumor response rates and less liver toxicity.